Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03084471
Title An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)
Acronym STRONG
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | GBR | FRA | DEU | CAN


No variant requirements are available.